SHSusanne A. Hahn

Susanne A. Hahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susanne A. Hahn has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A key role of GARP in the immune suppressive tumor microenvironment

    by Susanne A. Hahn, Annemarie Neuhoff, Jenny Landsberg, Jonathan Schupp, Daniela Eberts, Petra Leukel, Matthias Bros, Martin Weilbaecher, Detlef Schuppan, Stephan Grabbe, et al.

    In melanoma patients, one of the main reasons for tumor immune escape and therapy failure is the immunosuppressive tumor microenvironment. Herein, suppressive immune cells and inhibitory factors secreted by the tumor itself play a central role.


  • GARP inhibits allergic airway inflammation in a humanized mouse model

    by H. Meyer‐Martin, S. A. Hahn, H. Beckert, C. Belz, A. Heinz, H. Jonuleit, C. Becker, C. Taube, S. Korn, R. Buhl, et al.

    Background: Regulatory T cells (Treg) represent a promising target for novel treatment strategies in patients with inflammatory/allergic diseases. A soluble derivate of the Treg surface molecule glycoprotein A repetitions predominant (sGARP) has strong anti‐inflammatory and regulatory effects on human cells in vitro as well as in vivo through de novo induction of peripheral Treg. The aim of this study was to investigate the immunomodulatory function of sGARP and its possible role as a new therapeutic option in allergic diseases using a humanized mouse model.Methods: To analyze the therapeutic effects of sGARP, adult NOD/Scidγc−/− (NSG) mice received peripheral blood mononuclear cells (PBMC) derived from allergic patients with sensitization against birch allergen. Subsequently, allergic inflammation was induced in the presence of Treg alone or in combination with sGARP.Results: In comparison with mice that received Treg alone, additional treatment with sGARP reduced airway hyperresponsiveness (AHR), influx of neutrophils and macrophages into the bronchoalveolar lavage (BAL), and human CD45+ cells in the lungs. Furthermore, the numbers of mucus‐producing goblet cells and inflammatory cell infiltrates were reduced. To elucidate whether the mechanism of action of sGARP involves the TGF‐β receptor pathway, mice additionally received anti‐TGF‐β receptor II (TGF‐βRII) antibodies. Blocking the signaling of TGF‐β through TGF‐βRII abrogated the anti‐inflammatory effects of sGARP, confirming its essential role in inhibiting the allergic inflammation.Conclusion: Induction of peripheral tolerance via sGARP is a promising potential approach to treat allergic airway diseases.


  • Open Access

    Translating Treg Therapy in Humanized Mice

    by Susanne A. Hahn, Iris Bellinghausen, Bettina Trinschek, Christian Becker

    Regulatory T cells (Treg) control immune cell function as well as non-immunological processes. Their far-reaching regulatory activities suggest their functional manipulation as a means to sustainably and causally intervene with the course of diseases. Preclinical tools and strategies are however needed to further test and develop interventional strategies outside the human body. ‘Humanized’ mouse models consisting of, mice engrafted with human immune cells and tissues, provide new tools to analyze human Treg ontogeny, immunobiology and therapy. Here, we summarize the current state of humanized mouse models as a means to study human Treg function at the molecular level and to design strategies to harness these cells for therapeutic purposes.


  • 66

    by Susanne A. Hahn, Helmut Jonuleit, Andrea Tuettenberg